Opioid growth factor – opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer

Cancer treatment and survivorship statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer

(2012) Fan Cheng et al.   Molecular Cancer

Determining tamoxifen sensitivity using primary breast cancer tissue in collagen-based three-dimensional culture

(2011) Alexander D. Leeper et al.   BIOMATERIALS

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention

(2011) Victor G. Vogel   CURRENT DRUG TARGETS

The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice

(2011) Renee N. Donahue et al.   GYNECOLOGIC ONCOLOGY

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis

(2009) Renee N. Donahue et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers

(2009) Ian S. Zagon et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer

(2009) Diego M. Avella et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype

(2008) Monzur Rahman et al.   BREAST CANCER RESEARCH AND TREATMENT